Latest news with #PumaBiotechnology
Yahoo
15 hours ago
- Business
- Yahoo
Compass Therapeutics And 2 Other Promising Penny Stocks To Consider
As the U.S. stock market continues its rally, with major indices like the S&P 500 and Nasdaq reaching new all-time highs, investors are exploring diverse opportunities to capitalize on this momentum. Penny stocks, often perceived as relics of past trading days, still present intriguing prospects when backed by robust financials. In this article, we explore three penny stocks that stand out for their balance sheet strength and potential for significant returns, offering investors a chance to uncover hidden value in quality companies. Top 10 Penny Stocks In The United States Name Share Price Market Cap Financial Health Rating Waterdrop (WDH) $1.88 $669.08M ★★★★★★ WM Technology (MAPS) $1.13 $204.42M ★★★★★★ Puma Biotechnology (PBYI) $4.87 $245.31M ★★★★★★ Performance Shipping (PSHG) $1.84 $22.88M ★★★★★★ Tuniu (TOUR) $0.9326 $88.89M ★★★★★★ CI&T (CINT) $4.96 $696.85M ★★★★★☆ BAB (BABB) $0.904375 $6.46M ★★★★★★ Lifetime Brands (LCUT) $4.08 $82.7M ★★★★★☆ Resources Connection (RGP) $4.55 $149.03M ★★★★★★ TETRA Technologies (TTI) $3.97 $522.46M ★★★★★★ Click here to see the full list of 410 stocks from our US Penny Stocks screener. We're going to check out a few of the best picks from our screener tool. Compass Therapeutics Simply Wall St Financial Health Rating: ★★★★★★ Overview: Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for treating various human diseases in the United States, with a market cap of $438.36 million. Operations: Compass Therapeutics does not have reported revenue segments. Market Cap: $438.36M Compass Therapeutics, Inc. is a pre-revenue biopharmaceutical company with a market cap of US$438.36 million, focusing on antibody-based therapeutics. Despite being unprofitable and reporting increased losses recently, the company maintains a strong financial position with short-term assets of US$106.2 million exceeding both its short and long-term liabilities. It is debt-free and has not significantly diluted shareholders over the past year. The company's revenue is forecast to grow substantially, though it remains unprofitable with no near-term profitability expected. Recently added to multiple Russell Growth Indexes, Compass continues to attract attention in the biotech sector despite its current challenges. Jump into the full analysis health report here for a deeper understanding of Compass Therapeutics. Examine Compass Therapeutics' earnings growth report to understand how analysts expect it to perform. Stitch Fix Simply Wall St Financial Health Rating: ★★★★★★ Overview: Stitch Fix, Inc. operates an online platform offering a variety of apparel, shoes, and accessories for diverse customer segments in the United States, with a market cap of approximately $588.49 million. Operations: The company generates revenue of $1.28 billion from its online retail segment. Market Cap: $588.49M Stitch Fix, Inc., with a market cap of US$588.49 million, has been added to multiple Russell Growth Indexes, reflecting its growing visibility in the market. Despite being unprofitable and not expected to achieve profitability soon, it maintains a strong financial position with short-term assets of US$373.3 million exceeding both short and long-term liabilities. The company reported third-quarter sales of US$325.02 million and reduced net losses compared to the previous year, indicating some operational improvements. It is debt-free and has not significantly diluted shareholders recently, though insider selling has been significant over the past three months. Click here to discover the nuances of Stitch Fix with our detailed analytical financial health report. Assess Stitch Fix's future earnings estimates with our detailed growth reports. Stereotaxis Simply Wall St Financial Health Rating: ★★★★★★ Overview: Stereotaxis, Inc. designs, manufactures, and markets robotic systems and information systems for interventional laboratories globally, with a market cap of $234.31 million. Operations: The company generates revenue from its Surgical & Medical Equipment segment, totaling $31.81 million. Market Cap: $234.31M Stereotaxis, Inc., with a market cap of US$234.31 million, remains unprofitable and isn't forecast to achieve profitability in the near term. However, it has shown revenue growth potential, reporting US$8.8 million for Q2 2025 compared to US$4.5 million the previous year and projecting double-digit revenue growth for 2025. The company is debt-free and has a seasoned board with an average tenure of 8.5 years. Recent FDA clearance for its MAGiC Sweep catheter highlights advancements in robotic medical technology, potentially enhancing future revenue streams despite current financial challenges. Click to explore a detailed breakdown of our findings in Stereotaxis' financial health report. Evaluate Stereotaxis' prospects by accessing our earnings growth report. Key Takeaways Reveal the 410 hidden gems among our US Penny Stocks screener with a single click here. Want To Explore Some Alternatives? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include CMPX SFIX and STXS. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
15 hours ago
- Business
- Yahoo
KORU Medical Systems And 2 Other Penny Stocks To Watch For Growth
As the U.S. stock market continues to reach new heights, with major indices like the S&P 500 and Nasdaq Composite hitting all-time highs, investors are increasingly optimistic about future growth prospects. In this context, penny stocks—though often overlooked—remain a relevant area of interest for those seeking opportunities in smaller or newer companies. While traditionally seen as high-risk investments, certain penny stocks can offer compelling opportunities by combining balance sheet strength with long-term potential. Top 10 Penny Stocks In The United States Name Share Price Market Cap Financial Health Rating Waterdrop (WDH) $1.85 $654.61M ★★★★★★ WM Technology (MAPS) $1.20 $158.82M ★★★★★★ Puma Biotechnology (PBYI) $4.85 $185.87M ★★★★★★ Performance Shipping (PSHG) $1.8031 $22.27M ★★★★★★ Tuniu (TOUR) $0.9326 $87.75M ★★★★★★ Riverview Bancorp (RVSB) $4.94 $103.07M ★★★★★★ BAB (BABB) $0.89 $6.46M ★★★★★★ Lifetime Brands (LCUT) $3.65 $90.18M ★★★★★☆ Resources Connection (RGP) $4.47 $153.36M ★★★★★★ TETRA Technologies (TTI) $3.92 $522.46M ★★★★★★ Click here to see the full list of 418 stocks from our US Penny Stocks screener. Below we spotlight a couple of our favorites from our exclusive screener. KORU Medical Systems Simply Wall St Financial Health Rating: ★★★★★☆ Overview: KORU Medical Systems, Inc. develops, manufactures, and commercializes subcutaneous infusion solutions for the drug delivery market both in the United States and internationally, with a market cap of $183.09 million. Operations: The company generates revenue of $36.85 million from its Surgical & Medical Equipment segment. Market Cap: $183.09M KORU Medical Systems has demonstrated revenue growth, with second-quarter sales rising to US$10.19 million from US$8.43 million the previous year, and a reduced net loss of US$0.21 million compared to US$0.99 million a year ago. The company raised its full-year 2025 revenue guidance to between US$39.5 and $40.5 million, indicating confidence in continued growth despite ongoing unprofitability and negative return on equity (-27.32%). KORU's inclusion in multiple Russell indices may enhance visibility among investors, while its debt-free status and sufficient cash runway provide financial stability amid efforts to scale operations under new commercial leadership. Take a closer look at KORU Medical Systems' potential here in our financial health report. Explore KORU Medical Systems' analyst forecasts in our growth report. AbCellera Biologics Simply Wall St Financial Health Rating: ★★★★★★ Overview: AbCellera Biologics Inc. focuses on discovering and developing antibody-based medicines for unmet medical needs in the United States, with a market cap of approximately $1.34 billion. Operations: The company generates revenue primarily from its Discovery and Development of Antibodies segment, which accounted for $32.88 million. Market Cap: $1.34B AbCellera Biologics has shown significant revenue growth, with second-quarter earnings rising to US$17.08 million from US$7.32 million a year ago, though it remains unprofitable with a net loss of US$34.73 million for the quarter. The company is debt-free and its short-term assets of US$742.1 million surpass both short-term and long-term liabilities, indicating strong financial positioning despite ongoing losses and negative return on equity (-16.45%). Recent legal victories affirming patent validity bolster its intellectual property portfolio, while upcoming Phase 1 trials for antibody candidates ABCL575 and ABCL635 highlight potential advancements in its drug development pipeline. Click here to discover the nuances of AbCellera Biologics with our detailed analytical financial health report. Review our growth performance report to gain insights into AbCellera Biologics' future. Design Therapeutics Simply Wall St Financial Health Rating: ★★★★★★ Overview: Design Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on researching, designing, developing, and commercializing small molecule therapeutic drugs for genetic diseases in the United States with a market cap of $243.74 million. Operations: Design Therapeutics, Inc. has not reported any revenue segments. Market Cap: $243.74M Design Therapeutics is a pre-revenue company focused on developing treatments for genetic diseases, with recent progress in its RESTORE-FA trial for Friedreich ataxia. The company reported a net loss of US$19.08 million for the second quarter of 2025, reflecting increased losses compared to the previous year. Despite being unprofitable and having an inexperienced management team, Design has no debt and sufficient cash runway exceeding three years. Its short-term assets significantly outweigh liabilities, providing financial stability as it addresses FDA concerns regarding its investigational new drug application while continuing clinical trials in Australia. Click here and access our complete financial health analysis report to understand the dynamics of Design Therapeutics. Learn about Design Therapeutics' future growth trajectory here. Seize The Opportunity Access the full spectrum of 418 US Penny Stocks by clicking on this link. Searching for a Fresh Perspective? Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include KRMD ABCL and DSGN. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Business
- Yahoo
Barclays Maintains a Sell Rating on Puma Biotechnology (PBYI) With a $2 PT
Puma Biotechnology, Inc. (NASDAQ:PBYI) is one of the top most undervalued biotech stocks to buy now. In a report released on August 8, Gena Wang from Barclays maintained a Sell rating on Puma Biotechnology, Inc. (NASDAQ:PBYI) and set a price target of $2.00. A research scientist examining a biological sample to develop a new drug candidate. The rating update came after Puma Biotechnology, Inc. (NASDAQ:PBYI) reported its fiscal Q2 2025 results on August 7. Product revenue net for fiscal Q2 2025 came up to $49.2 million, up from $44.4 million in fiscal Q2 2024. The product revenue net consisted solely of revenue from sales of NERLYNX, which is Puma Biotechnology, Inc.'s (NASDAQ:PBYI) first commercial product. Product revenue net in the first six months of 2025 was $92.3 million, up from $84.6 million in the same time period in 2024. Puma Biotechnology, Inc. (NASDAQ:PBYI) is a biopharmaceutical company involved in the acquisition and development of innovative products to treat different kinds of cancers. The company's focus is on the in-licensing drug candidates that are either in the process of or have already obtained initial clinical testing to treat cancer. It then endeavors to develop these drug candidates further for commercial use. While we acknowledge the potential of PBYI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
5 days ago
- Business
- Yahoo
Results: Puma Biotechnology, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
The investors in Puma Biotechnology, Inc.'s (NASDAQ:PBYI) will be rubbing their hands together with glee today, after the share price leapt 20% to US$3.69 in the week following its second-quarter results. Revenues were US$52m, approximately in line with whatthe analyst expected, although statutory earnings per share (EPS) crushed expectations, coming in at US$0.12, an impressive 25% ahead of estimates. Following the result, the analyst has updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. We thought readers would find it interesting to see the analyst latest (statutory) post-earnings forecasts for next year. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. After the latest results, the consensus from Puma Biotechnology's sole analyst is for revenues of US$216.0m in 2025, which would reflect a definite 9.3% decline in revenue compared to the last year of performance. Statutory earnings per share are expected to tumble 54% to US$0.44 in the same period. In the lead-up to this report, the analyst had been modelling revenues of US$220.0m and earnings per share (EPS) of US$0.48 in 2025. So it looks like there's been a small decline in overall sentiment after the recent results - there's been no major change to revenue estimates, but the analyst did make a small dip in their earnings per share forecasts. View our latest analysis for Puma Biotechnology It might be a surprise to learn that the consensus price target fell 36% to US$3.00, with the analyst clearly linking lower forecast earnings to the performance of the stock price. Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. One more thing stood out to us about these estimates, and it's the idea that Puma Biotechnology's decline is expected to accelerate, with revenues forecast to fall at an annualised rate of 18% to the end of 2025. This tops off a historical decline of 1.0% a year over the past five years. Compare this against analyst estimates for companies in the broader industry, which suggest that revenues (in aggregate) are expected to grow 19% annually. So it's pretty clear that, while it does have declining revenues, the analyst also expect Puma Biotechnology to suffer worse than the wider industry. The Bottom Line The most important thing to take away is that the analyst downgraded their earnings per share estimates, showing that there has been a clear decline in sentiment following these results. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. The consensus price target fell measurably, with the analyst seemingly not reassured by the latest results, leading to a lower estimate of Puma Biotechnology's future valuation. With that said, the long-term trajectory of the company's earnings is a lot more important than next year. At least one analyst has provided forecasts out to 2027, which can be seen for free on our platform here. You should always think about risks though. Case in point, we've spotted 1 warning sign for Puma Biotechnology you should be aware of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
10-06-2025
- Business
- Yahoo
With 57% ownership, Puma Biotechnology, Inc. (NASDAQ:PBYI) boasts of strong institutional backing
Significantly high institutional ownership implies Puma Biotechnology's stock price is sensitive to their trading actions 50% of the business is held by the top 8 shareholders 15% of Puma Biotechnology is held by insiders AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. A look at the shareholders of Puma Biotechnology, Inc. (NASDAQ:PBYI) can tell us which group is most powerful. And the group that holds the biggest piece of the pie are institutions with 57% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). Because institutional owners have a huge pool of resources and liquidity, their investing decisions tend to carry a great deal of weight, especially with individual investors. Therefore, a good portion of institutional money invested in the company is usually a huge vote of confidence on its future. Let's take a closer look to see what the different types of shareholders can tell us about Puma Biotechnology. View our latest analysis for Puma Biotechnology Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices. Puma Biotechnology already has institutions on the share registry. Indeed, they own a respectable stake in the company. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Puma Biotechnology, (below). Of course, keep in mind that there are other factors to consider, too. Since institutional investors own more than half the issued stock, the board will likely have to pay attention to their preferences. We note that hedge funds don't have a meaningful investment in Puma Biotechnology. The company's CEO Alan Auerbach is the largest shareholder with 14% of shares outstanding. With 7.9% and 7.8% of the shares outstanding respectively, Acorn Bioventures and BlackRock, Inc. are the second and third largest shareholders. We did some more digging and found that 8 of the top shareholders account for roughly 50% of the register, implying that along with larger shareholders, there are a few smaller shareholders, thereby balancing out each others interests somewhat. While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There is some analyst coverage of the stock, but it could still become more well known, with time. While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO. Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group. Our most recent data indicates that insiders own a reasonable proportion of Puma Biotechnology, Inc.. Insiders have a US$28m stake in this US$185m business. This may suggest that the founders still own a lot of shares. You can click here to see if they have been buying or selling. The general public, who are usually individual investors, hold a 20% stake in Puma Biotechnology. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies. With an ownership of 7.9%, private equity firms are in a position to play a role in shaping corporate strategy with a focus on value creation. Some investors might be encouraged by this, since private equity are sometimes able to encourage strategies that help the market see the value in the company. Alternatively, those holders might be exiting the investment after taking it public. While it is well worth considering the different groups that own a company, there are other factors that are even more important. For instance, we've identified 1 warning sign for Puma Biotechnology that you should be aware of. If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
